如何改进治疗性抗体的安全性和疗效特征  

How to improve safety and efficacy profiles of therapeutic antibodies

出　　处：《经济导报（医药技术）》2009年第3期24-27,共4页

摘　　要：自从首次发现单克隆抗体（MAbs）在医药和工业中可能存在的应用价值后，它们已被经常·性地用于研究和诊断试验室中，而对其用于治疗的可能·性的研究正在以指数级的速度推进。现在，MAbs成为了发展最快的一类蛋白治疗性抗体，当前主要被研发用于治疗癌症、自身免疫性疾病、感染性疾病和炎。性疾病。它们代表了生物技术行业内出现的销量最大的一类制品一治疗’性抗体。截止2008年年底，美国治疗性抗体的市场估计价值达40bn美元，预计抗体很快就会超越较大制药市场的销售额。Since it was first noted that monoclonal antibodies （MAbs） could be valuable for medicine and industrial use they have become routinely used in research and diagnostic laboratories and their potential as therapeutics has continued to be explored at an exponential rate. MAbs now comprise the fastest growing class of protein therapeutics and are currently being used and developed primarily to treat cancers, autoimmune diseases, infectious diseases and inflammatory diseases. They represent some of the largest selling products to emerge from the biotechnology industry - by 2008 the US therapeutic antibody market was estimated to be worth around USD 40bn - and antibodies are soon expected to outpace the sales of the larger pharmaceutical markets.

关 键 词：治疗性抗体 自身免疫性疾病 安全性 疗效 制药市场 单克隆抗体 感染性疾病 生物技术 

分 类 号：R392.11[医药卫生—免疫学] R593.2[医药卫生—基础医学]